PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?

J Thorac Oncol. 2016 Nov;11(11):e142-e144. doi: 10.1016/j.jtho.2016.07.025.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • B7-H1 Antigen / genetics*
  • Biomarkers / analysis*
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Cell Cycle Checkpoints / drug effects
  • Cell Cycle Checkpoints / immunology*
  • Humans
  • In Situ Hybridization / methods*
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / immunology
  • RNA, Messenger / genetics*

Substances

  • Antineoplastic Agents
  • B7-H1 Antigen
  • Biomarkers
  • CD274 protein, human
  • RNA, Messenger